Gossamer Bio, Inc. (GOSS)
8.89
-0.02
(-0.17%)
USD |
NASDAQ |
Oct 15, 16:00
9.05
+0.16
(+1.80%)
After-Hours: 04:10
Gossamer Bio Cash from Operations (TTM) : -164.59M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -164.59M |
| March 31, 2026 | -170.26M |
| December 31, 2025 | -171.27M |
| September 30, 2025 | -158.43M |
| June 30, 2025 | -154.30M |
| March 31, 2025 | 9.11M |
| December 31, 2024 | -3.468M |
| September 30, 2024 | -1.411M |
| June 30, 2024 | -3.872M |
| March 31, 2024 | -158.47M |
| December 31, 2023 | -159.16M |
| September 30, 2023 | -173.46M |
| June 30, 2023 | -175.97M |
| March 31, 2023 | -186.54M |
| Date | Value |
|---|---|
| December 31, 2022 | -187.03M |
| September 30, 2022 | -179.81M |
| June 30, 2022 | -184.85M |
| March 31, 2022 | -183.48M |
| December 31, 2021 | -188.89M |
| September 30, 2021 | -185.12M |
| June 30, 2021 | -188.01M |
| March 31, 2021 | -182.96M |
| December 31, 2020 | -176.36M |
| September 30, 2020 | -183.76M |
| June 30, 2020 | -174.94M |
| March 31, 2020 | -169.36M |
| December 31, 2019 | -144.83M |
| September 30, 2019 | -125.72M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| United Therapeutics Corp. | 1.682B |
| Arbutus Biopharma Corp. | -24.13M |
| Kura Oncology, Inc. | -111.76M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |